Histogen Receives $6M in Series D Funding

histogenHistogen, Inc., a San Diego, CA-based regenerative medicine company, received a $6m private equity investment.

The Series D round was led by Pineworld Capital Ltd, an affiliate of Huapont Life Sciences, made the investment.

The company intends to use the funds to continue development of its Hair Stimulating Complex (HSC) in the United States, as well as to begin preparations for an Initial Public Offering (IPO).

Led by Dr. Gail Naughton, CEO and Chairman, Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the company has developed its product portfolio.



Join the discussion